PTC596|PTC 596|CAS 1610964-64-1|DC Chemicals

Cas No.:	1610964-64-1
Chemical Name:	5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine
Synonyms:	PTC596 ,PTC-596 ,PTC 596
SMILES:	NC1N=C(N2C(C)=NC3C2=CC(=CC=3)F)N=C(NC2C=CC(C(F)(F)F)=CC=2)C=1F
Formula:	C₁₉H₁₃F₅N₆
M.Wt:	420.33
Purity:	>98%
Sotrage:	C[C@@H](C1=CC=CC=C1)NC(=O)/C(=C/C2=NC(=CC=C2)Br)/C#N

Description:	PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. PTC596 targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1, leading to its degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells[1][2].
Target:	BMI-1[1]
References:	[1]. Nishida Y, et al. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J. 2017 Feb 17;7(2):e527. [2]. BMI1 inhibitor PTC596

Cat. No.	Product name	Field of application
DC28030	PTC596	PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. PTC596 targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1, leading to its degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.
DC48112	Ac-YVAD-cmk	Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective caspase-1 (IL-1beta converting enzyme, ICE)) inhibitor with neuroprotective and anti-inflammatory effects. Ac-YVAD-cmk effectively suppresses the expression of IL-1β and IL-18. Ac-YVAD-cmk inhibits pyroptosis in many diseases.
DC45548	Boc-Asp(OMe)-fluoromethyl ketone	Boc-Asp(OME)-Fluoromethyl Ketone is a broad range caspase inhibitor that inhibits Fas-mediated phagocytosis and oxidative rupture inhibition, but does not affect the chemotactic activity of IL-8.
DC42284	APG-1387	APG-1387, a bivalent SMAC mimetic, is an IAP antagonist that can induce proteasomal degradation of IAPs. APG-1387 sensitizes immune-mediated cell apoptosis in cancers. APG-1387 can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma.
DC10851	PK11000	PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding.
DC5080	Belnacasan (VX-765)	VX-765 is a novel Caspase-1 inhibitor with an IC 50 of 0.8nM being investigated for the treatment of epilepsy, currently being developed by Vertex.
DC4119	YM155	YM155 is a potent IAP (inhibitor of apoptosis proteins) inhibitor for survivin with IC50 of 0.54 nM.
DC9504	YH239-EE	YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent
DC10373	WEHI-345	WEHI-345 is a potent and selective inhibitor of RIPK2, with IC50 of 0.13 μM.
DC7950	UMI-77	UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.